These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 2010558)

  • 21. Review of the Food and Drug Administration's Center for Drug Evaluation and Research Program for New Molecular Entities: Trends and Regulatory Requirements in Acknowledgment Letters and Filing Communications.
    Camp JR; Fuhs JV; Beattie SD; Asay RL; Hoffman RD
    Ther Innov Regul Sci; 2021 May; 55(3):568-582. PubMed ID: 33492633
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ethical imperatives of timely access to orphan drugs: is possible to reconcile economic incentives and patients' health needs?
    Rodriguez-Monguio R; Spargo T; Seoane-Vazquez E
    Orphanet J Rare Dis; 2017 Jan; 12(1):1. PubMed ID: 28057032
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Regulatory characteristics and pivotal study design of US Food and Drug Administration approval of drugs for major vs. minor cancer.
    Yamashita K; Kaneko M; Narukawa M
    Eur J Clin Pharmacol; 2019 Sep; 75(9):1193-1200. PubMed ID: 31129731
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Status and thoughts of Chinese patent medicines seeking approval in the US market.
    Lei X; Chen J; Liu CX; Lin J; Lou J; Shang HC
    Chin J Integr Med; 2014 Jun; 20(6):403-8. PubMed ID: 24952167
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efaproxiral: GSJ 61, JP 4, KDD 86, RS 4, RSR 13.
    Drugs R D; 2005; 6(3):178-85. PubMed ID: 15869322
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Trends in development and approval times for new therapeutics in the United States.
    Reichert JM
    Nat Rev Drug Discov; 2003 Sep; 2(9):695-702. PubMed ID: 12951576
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Applications for FDA approval to market a dew drug: patent submission and listing requirements and application of 30-month stays on approval of abbreviated new drug applications certifying that a patent claiming a drug is invalid or will not be infringed. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2003 Jun; 68(117):36675-712. PubMed ID: 12814136
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Examination of risk evaluation and mitigation strategies and drug safety in the US.
    Rodriguez-Monguio R; Spielberger K; Seoane-Vazquez E
    Res Social Adm Pharm; 2014; 10(1):232-8. PubMed ID: 23611865
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lessons learned from independent central review.
    Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
    Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Abarelix: abarelix-depot-F, abarelix-depot-M, abarelix-L, PPI 149, R 3827.
    Drugs R D; 2003; 4(3):161-6. PubMed ID: 12757402
    [TBL] [Abstract][Full Text] [Related]  

  • 31. New biopharmaceuticals in the USA: trends in development and marketing approvals 1995-1999.
    Reichert JM
    Trends Biotechnol; 2000 Sep; 18(9):364-9. PubMed ID: 10942959
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Drugs, Devices, and the FDA: Part 1: An Overview of Approval Processes for Drugs.
    Van Norman GA
    JACC Basic Transl Sci; 2016 Apr; 1(3):170-179. PubMed ID: 30167510
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The "treatment IND (investigational new drugs)": public policy considerations.
    Roberts C; Palumbo FB
    J Pharm Mark Manage; 1988; 3(1):41-59. PubMed ID: 10290888
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oblimersen: Augmerosen, BCL-2 antisense oligonucleotide - Genta, G 3139, GC 3139, oblimersen sodium.
    Drugs R D; 2007; 8(5):321-34. PubMed ID: 17767397
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Investigational drug tracking: Phases I-III and NDA submissions--Part I.
    Grant KL
    Hosp Pharm; 1994 Sep; 29(9):830-6, 839-44, 847-52 passim. PubMed ID: 10137064
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Investigating the landscape of US orphan product approvals.
    Miller KL; Lanthier M
    Orphanet J Rare Dis; 2018 Oct; 13(1):183. PubMed ID: 30348193
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Recent drug approvals from the US FDA and EMEA: what the future holds.
    Pevarello P
    Future Med Chem; 2009 Apr; 1(1):35-48. PubMed ID: 21426069
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The investigator-sponsored IND in clinical trials.
    Haakenson C; Fye CL; Sather MR; Toussaint DJ
    Control Clin Trials; 1987 Jun; 8(2):101-9. PubMed ID: 3608504
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Therapeutic recombinant proteins: trends in US approvals 1982 to 2002.
    Reichert JM; Paquette C
    Curr Opin Mol Ther; 2003 Apr; 5(2):139-47. PubMed ID: 12772503
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Building a drug development database: challenges in reliable data availability.
    Audibert C; Romine M; Caze A; Daniel G; Leff J; McClellan M
    Drug Dev Ind Pharm; 2017 Jan; 43(1):74-78. PubMed ID: 27494335
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.